Loading
Retinal Development and Disorders · Journal article
Clinical and Experimental Ophthalmology · September 1, 2026
Early or partial results. Treat as a signal, not a conclusion.
This study describes a CRISPR-generated Kcnv2 E151X mouse model that reproduces key structural and functional features of human KCNV2-associated retinopathy, including markedly reduced photopic responses, supernormal rod responses, glial activation, cone loss, and photoreceptor layer thinning. The model is presented as a validated preclinical platform for mechanistic and therapeutic research, not as evidence of efficacy or safety in humans.
Preclinical animal model characterization study. Kcnv2 E151X mutant mice generated via CRISPR/Cas9; control comparison group type not specified.. Intervention: CRISPR/Cas9-generated Kcnv2 E151X mutation (early stop at position E151).. Compared with: Control mice (strain, genotype, and number not stated)..
Mutant mice showed markedly reduced photopic responses consistent with cone dysfunction in human disease. Supernormal rod phenotype (paradoxically large rod response to bright light) was reproduced in the mutant line. Strong glial fibrillary acidic protein upregulation observed in mutant retinas, indicating glial activation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This model may support future preclinical evaluation of gene therapy or pharmacological interventions for KCNV2-associated retinopathy. However, animal model results do not directly predict human efficacy or safety and require subsequent clinical validation.
This is a proof-of-concept animal model study establishing that a mutant mouse line recapitulates disease hallmarks; it is descriptive and preclinical, designed to enable future mechanistic and therapeutic work rather than to test an intervention.
As stated by the source record.
Quoted from the source exactly as published.
This model may support future preclinical evaluation of gene therapy or pharmacological interventions for KCNV2-associated retinopathy. However, animal model results do not directly predict human efficacy or safety and require subsequent clinical validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: KCNV2-associated retinopathy is a rare inherited retinal dystrophy caused by variants in the KCNV2 gene, leading to disrupted photoreceptor behaviour and progressive deterioration of vision. Patients have characteristic electroretinography abnormalities, including reduced cone response, delayed and reduced rod response to low light flashes and paradoxically large rod-driven response to bright flashes of light. To model this condition, we have generated a Kcnv2 E151X mouse line and assessed its structural and functional retinal features. METHODS: We have employed CRISPR/Cas 9 gene editing technology to generate a mouse line with an early stop mutation in position E151-orthologous to the commonly encountered E143X mutation in humans-and performed a combination of immunohistochemistry and Western blot to confirm the absence of the full-length KCNV2-encoded protein, Kv8.2. Next, to assess how closely it models the human disease, we have characterised the KCNV2 mutant mouse line at histological and functional levels, via immunohistochemistry and electroretinography experiments, respectively. RESULTS: Kcnv2 mutant mice showed markedly reduced photopic responses and reproduced the supernormal rod phenotype described in affected individuals. In the morphological context, mutant retinas demonstrated strong glial fibrillary acidic protein upregulation together with reduced cone arrestin positive cell counts and photoreceptor layers, indicating photoreceptor loss. CONCLUSIONS: The Kcnv2 mutant mouse line replicates key functional and structural hallmarks of KCNV2-associated retinopathy. This model provides a relevant platform for mechanistic studies and preclinical evaluation of gene-based or pharmacological therapies targeting cone and rod photoreceptor dysfunction.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.